Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Revance Therapeutics (RVNC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Revance Therapeutics Announces Two Recent Additions to Its Management Team

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its...

RVNC : 30.75 (+0.65%)
Revance Releases First Quarter 2018 Results

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced results for the first...

RVNC : 30.75 (+0.65%)
Pivotal SAKURA Phase 3 Clinical Data to be Featured in Oral and Poster Presentations at The Aesthetic Meeting 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced oral and ePoster presentations...

RVNC : 30.75 (+0.65%)
Revance Therapeutics to Release First Quarter 2018 Financial Results on Tuesday, May 8, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will...

RVNC : 30.75 (+0.65%)
Revance Investor Day Highlights New Neuroscience Indications in Development

--- Initiating Phase 3 pivotal trial for cervical dystonia in current quarter -

RVNC : 30.75 (+0.65%)
Look for Shares of Revance Therapeu to Potentially Pullback after Yesterday's 5.27% Rise

Revance Therapeu (NASDAQ:RVNC) traded in a range yesterday that spanned from a low of $30.55 to a high of $31.95. Yesterday, the shares gained 5.3%, which took the trading range above the 3-day high...

RVNC : 30.75 (+0.65%)
Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced the appointments...

RVNC : 30.75 (+0.65%)
Revance to Host Investor Day on April 19, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the...

RVNC : 30.75 (+0.65%)
Revance to Participate in the Needham Healthcare Conference

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the...

RVNC : 30.75 (+0.65%)
Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the...

RVNC : 30.75 (+0.65%)
Revance Releases Fourth Quarter and Full Year 2017 Results

---Cash and investments of approximately $283 million as of December 31, 2017-

RVNC : 30.75 (+0.65%)
Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics

Mylan N.V. (NASDAQ: MYL) and Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to...

MYL : 39.33 (-0.76%)
RVNC : 30.75 (+0.65%)
Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics

HERTFORDSHIRE, England and PITTSBURGH , and NEWARK, Calif. , Feb. 28, 2018 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced a global...

MYL : 39.33 (-0.76%)
RVNC : 30.75 (+0.65%)
New Research Coverage Highlights PROS, BioLife Solutions, Home BancShares, Revance Therapeutics, HomeStreet, and Ennis -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PROS Holdings, Inc. (NYSE:PRO),...

HMST : 27.65 (-1.60%)
BLFS : 9.51 (+5.08%)
EBF : 18.25 (-0.27%)
PRO : 35.42 (-0.70%)
HOMB : 23.47 (-0.42%)
RVNC : 30.75 (+0.65%)
Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced that the...

RVNC : 30.75 (+0.65%)
Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, today announced presentation...

RVNC : 30.75 (+0.65%)
Revance Therapeu Shares Up 23.9% Since SmarTrend's Buy Recommendation (RVNC)

SmarTrend identified an Uptrend for Revance Therapeu (NASDAQ:RVNC) on November 30th, 2017 at $27.42. In approximately 2 months, Revance Therapeu has returned 23.88% as of today's recent price of $33.97....

RVNC : 30.75 (+0.65%)
Global Botulinum Toxin Market Report 2018: Size, Trends and Forecasts 2017-2021 Featuring Allergan Plc, Ipsen & Revance Therapeutics, Inc - ResearchAndMarkets.com

The "Global Botulinum Toxin Market: Size, Trends and Forecasts (2017-2021)" report has been added to ResearchAndMarkets.com's offering.

AGN : 153.66 (-1.47%)
RVNC : 30.75 (+0.65%)
24.9% Return Seen to Date on SmarTrend Revance Therapeu Call (RVNC)

SmarTrend identified an Uptrend for Revance Therapeu (NASDAQ:RVNC) on November 30th, 2017 at $27.42. In approximately 2 months, Revance Therapeu has returned 24.89% as of today's recent price of $34.25....

RVNC : 30.75 (+0.65%)
26.0% Return Seen to Date on SmarTrend Revance Therapeu Call (RVNC)

SmarTrend identified an Uptrend for Revance Therapeu (NASDAQ:RVNC) on November 30th, 2017 at $27.42. In approximately 1 month, Revance Therapeu has returned 25.98% as of today's recent price of $34.55....

RVNC : 30.75 (+0.65%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar